Skip to main navigation Skip to search Skip to main content

A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose

  • Kyle D. Holen
  • , Chandra P. Belani
  • , George Wilding
  • , Suresh Ramalingam
  • , Jennifer L. Volkman
  • , Ramesh K. Ramanathan
  • , Lakshmi S. Vasist
  • , Carolyn J. Bowen
  • , Jeffrey P. Hodge
  • , Mohammed M. Dar
  • , Peter T.C. Ho

Research output: Contribution to journal › Article › peer-review

Abstract

Purpose: To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), safety, pharmacokinetics, and pharmacodynamics of SB-743921 when administered as a 1-h infusion every 21 days to patients with advanced solid tumors or relapsed/refractory lymphoma. Methods: Patients who failed prior standard therapy or those without any standard options were eligible. Fortyfour patients were enrolled using an initial accelerated dose-escalation phase followed by a standard dose-escalation phase. An additional 20 patients were enrolled at the recommended phase II dose to obtain additional safety and pharmacokinetic data. The doses evaluated ranged from 2 to 8 mg/m2. The pharmacokinetics of SB-743921 was evaluated at 19 time-points over 48 h following during administration during cycle 1. Toxicity was assessed by the NCI Common Terminology Criteria version 3.0. Response evaluation was performed every 6 weeks. Results: The most common and consistent DLT was neutropenia. Other DLTs observed included hypophosphatemia, pulmonary emboli, SVC syndrome, transaminitis, hyponatremia, and hyperbilirubinemia. The MTD of SB-743921 as a 1-h infusion every 21 days was established as 4 mg/m2. The maximum plasma concentration and area under the plasma concentration time curve appeared to increase proportionally to dose. One durable objective response was seen in a patient with metastatic cholangiocarcinoma who was on treatment 11 months and 6 patients had stable disease for over four cycles. Conclusions: The recommended phase II dose of SB-743921 on this specific schedule of a 1-h infusion every 3 weeks is 4 mg/m2. The promising efficacy and lack of severe toxicities in this study warrant the continued development of SB-743921.

Original languageEnglish (US)
Pages (from-to)447-454
Number of pages8
JournalCancer chemotherapy and pharmacology
Volume67
Issue number2
DOIs
StatePublished - Feb 2011
Externally publishedYes

Keywords

  • Kinesin spindle protein
  • Mitosis
  • Pharmacokinetics
  • Phase I
  • SB-743921
  • Safety

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose'. Together they form a unique fingerprint.

Cite this